AstraZeneca PLC (AZN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AstraZeneca PLC (AZN) has a cash flow conversion efficiency ratio of 0.071x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX3.36 Billion ≈ $408.69K USD) by net assets (GBX47.38 Billion ≈ $5.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of AstraZeneca PLC to measure how many days the company can operate on defensive assets alone.
AstraZeneca PLC - Cash Flow Conversion Efficiency Trend (1990–2025)
This chart illustrates how AstraZeneca PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
AstraZeneca PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AstraZeneca PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chicony Electronics Co Ltd
TW:2385
|
0.036x |
|
Bloomage Biotechnology Corp Ltd
SHG:688363
|
0.013x |
|
Sunway Construction Group Bhd
KLSE:5263
|
-0.090x |
|
Olin Corporation
NYSE:OLN
|
0.160x |
|
Fuchs Petrolub SE
XETRA:FPE
|
0.034x |
|
IGB Real Estate Investment Trust
KLSE:5227
|
0.016x |
|
Sime Darby Property Bhd
KLSE:5288
|
-0.006x |
|
Malaysian Pacific Industries
KLSE:3867
|
0.040x |
Annual Cash Flow Conversion Efficiency for AstraZeneca PLC (1990–2025)
The table below shows the annual cash flow conversion efficiency of AstraZeneca PLC from 1990 to 2025. For the full company profile with market capitalisation and key ratios, see AZN market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | GBX48.72 Billion ≈ $5.93 Million |
GBX14.57 Billion ≈ $1.77 Million |
0.299x | +3.09% |
| 2024-12-31 | GBX40.87 Billion ≈ $4.97 Million |
GBX11.86 Billion ≈ $1.44 Million |
0.290x | +9.87% |
| 2023-12-31 | GBX39.17 Billion ≈ $4.77 Million |
GBX10.35 Billion ≈ $1.26 Million |
0.264x | -0.20% |
| 2022-12-31 | GBX37.06 Billion ≈ $4.51 Million |
GBX9.81 Billion ≈ $1.19 Million |
0.265x | +74.37% |
| 2021-12-31 | GBX39.29 Billion ≈ $4.78 Million |
GBX5.96 Billion ≈ $725.52K |
0.152x | -50.54% |
| 2020-12-31 | GBX15.64 Billion ≈ $1.90 Million |
GBX4.80 Billion ≈ $583.90K |
0.307x | +50.87% |
| 2019-12-31 | GBX14.60 Billion ≈ $1.78 Million |
GBX2.97 Billion ≈ $361.24K |
0.203x | +9.12% |
| 2018-12-31 | GBX14.04 Billion ≈ $1.71 Million |
GBX2.62 Billion ≈ $318.53K |
0.186x | -13.30% |
| 2017-12-31 | GBX16.64 Billion ≈ $2.02 Million |
GBX3.58 Billion ≈ $435.34K |
0.215x | -13.54% |
| 2016-12-31 | GBX16.67 Billion ≈ $2.03 Million |
GBX4.14 Billion ≈ $504.33K |
0.249x | +37.96% |
| 2015-12-31 | GBX18.44 Billion ≈ $2.24 Million |
GBX3.32 Billion ≈ $404.43K |
0.180x | -49.83% |
| 2014-12-31 | GBX19.65 Billion ≈ $2.39 Million |
GBX7.06 Billion ≈ $858.75K |
0.359x | +12.89% |
| 2013-12-31 | GBX23.25 Billion ≈ $2.83 Million |
GBX7.40 Billion ≈ $900.37K |
0.318x | +9.71% |
| 2012-12-31 | GBX23.95 Billion ≈ $2.91 Million |
GBX6.95 Billion ≈ $845.37K |
0.290x | -12.94% |
| 2011-12-31 | GBX23.47 Billion ≈ $2.86 Million |
GBX7.82 Billion ≈ $951.59K |
0.333x | -26.96% |
| 2010-12-31 | GBX23.41 Billion ≈ $2.85 Million |
GBX10.68 Billion ≈ $1.30 Million |
0.456x | -19.08% |
| 2009-12-31 | GBX20.82 Billion ≈ $2.53 Million |
GBX11.74 Billion ≈ $1.43 Million |
0.564x | +3.58% |
| 2008-12-31 | GBX16.06 Billion ≈ $1.95 Million |
GBX8.74 Billion ≈ $1.06 Million |
0.544x | +8.11% |
| 2007-12-31 | GBX14.91 Billion ≈ $1.81 Million |
GBX7.51 Billion ≈ $913.75K |
0.504x | +0.90% |
| 2006-12-31 | GBX15.42 Billion ≈ $1.88 Million |
GBX7.69 Billion ≈ $936.02K |
0.499x | +1.32% |
| 2005-12-31 | GBX13.69 Billion ≈ $1.67 Million |
GBX6.74 Billion ≈ $820.43K |
0.493x | +46.52% |
| 2004-12-31 | GBX14.50 Billion ≈ $1.76 Million |
GBX4.87 Billion ≈ $592.90K |
0.336x | +30.45% |
| 2003-12-31 | GBX13.26 Billion ≈ $1.61 Million |
GBX3.42 Billion ≈ $415.63K |
0.258x | -40.17% |
| 2002-12-31 | GBX11.22 Billion ≈ $1.37 Million |
GBX4.83 Billion ≈ $588.04K |
0.431x | +53.24% |
| 2001-12-31 | GBX9.63 Billion ≈ $1.17 Million |
GBX2.71 Billion ≈ $329.30K |
0.281x | +14.89% |
| 2000-12-31 | GBX9.55 Billion ≈ $1.16 Million |
GBX2.34 Billion ≈ $284.22K |
0.245x | +178.60% |
| 1999-12-31 | GBX10.35 Billion ≈ $1.26 Million |
GBX908.55 Million ≈ $110.54K |
0.088x | +9.62% |
| 1998-12-31 | GBX10.98 Billion ≈ $1.34 Million |
GBX879.74 Million ≈ $107.04K |
0.080x | -61.15% |
| 1997-12-31 | GBX3.62 Billion ≈ $440.89K |
GBX747.21 Million ≈ $90.91K |
0.206x | -4.16% |
| 1996-12-31 | GBX3.66 Billion ≈ $445.48K |
GBX787.75 Million ≈ $95.85K |
0.215x | +11.55% |
| 1995-12-31 | GBX3.04 Billion ≈ $369.44K |
GBX585.64 Million ≈ $71.25K |
0.193x | -15.95% |
| 1994-12-31 | GBX2.73 Billion ≈ $331.56K |
GBX625.36 Million ≈ $76.09K |
0.229x | -24.42% |
| 1993-12-31 | GBX2.32 Billion ≈ $282.74K |
GBX705.58 Million ≈ $85.85K |
0.304x | -75.00% |
| 1992-12-31 | GBX169.87 Million ≈ $20.67K |
GBX206.27 Million ≈ $25.10K |
1.214x | +120.37% |
| 1991-12-31 | GBX916.88 Million ≈ $111.56K |
GBX505.22 Million ≈ $61.47K |
0.551x | -53.33% |
| 1990-12-31 | GBX682.84 Million ≈ $83.08K |
GBX806.30 Million ≈ $98.10K |
1.181x | -- |
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splend… Read more